Michael Fricker
Overview
Explore the profile of Michael Fricker including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
50
Citations
1974
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Liu G, Hsu A, Geirnaert S, Cong C, Nair P, Shen S, et al.
Mol Ther
. 2025 Jan;
33(3):917-932.
PMID: 39838644
Vitronectin (VTN) is an important extracellular matrix protein in tissue remodeling, but its role in chronic obstructive pulmonary disease (COPD) is unknown. We show that VTN regulates tissue remodeling through...
2.
Hamada Y, Gibson P, Harvey E, Stevens S, Lewthwaite H, Fricker M, et al.
J Allergy Clin Immunol Pract
. 2024 Nov;
13(2):333-342.e9.
PMID: 39515519
Background: Mepolizumab can induce an early response and clinical remission in people with severe eosinophilic asthma (SEA). Objective: To find whether early response to mepolizumab (100 mg) could predict future...
3.
Hamada Y, Thomas D, Harvey E, Stevens S, Fricker M, Lewthwaite H, et al.
Eur Respir J
. 2024 Oct;
65(1).
PMID: 39401859
Background: Patients with severe eosinophilic asthma, characterised by a high disease burden, benefit from mepolizumab, which improves symptoms and reduces exacerbations, potentially leading to clinical remission in a subgroup. This...
4.
Fricker M, Harrington J, Hiles S, Gibson P
Allergy
. 2024 Aug;
79(11):3118-3128.
PMID: 39115364
Background: Eosinophils are key therapeutic targets in severe asthma that are suppressed by IL5 (mepolizumab) and IL5 receptor (benralizumab) blockade. The effect of IL5 pathway biologics on recently described homeostatic...
5.
Song Z, Meng Y, Fricker M, Li X, Tian H, Tan Y, et al.
Heliyon
. 2024 May;
10(9):e30612.
PMID: 38742057
Chronic obstructive pulmonary disease (COPD) is a major cause of morbidity and healthcare burden worldwide. The progression of COPD is a combination of genetic predisposition and environmental factors, primarily cigarette...
6.
Budden K, Shukla S, Bowerman K, Vaughan A, Gellatly S, Wood D, et al.
Gut
. 2024 Feb;
73(5):751-769.
PMID: 38331563
Objective: Chronic obstructive pulmonary disease (COPD) is a major cause of global illness and death, most commonly caused by cigarette smoke. The mechanisms of pathogenesis remain poorly understood, limiting the...
7.
Liu G, Jarnicki A, Paudel K, Lu W, Wadhwa R, Philp A, et al.
Eur Respir J
. 2022 Jul;
60(6).
PMID: 35777766
Background: COPD is the third leading cause of death worldwide. Cigarette smoke (CS)-induced chronic inflammation inducing airway remodelling, emphysema and impaired lung function is the primary cause. Effective therapies are...
8.
Niessen N, Fricker M, McDonald V, Gibson P
Ann Allergy Asthma Immunol
. 2022 Apr;
129(2):150-159.
PMID: 35487388
T2-low asthma is an often severe asthma subtype with limited treatment options and biologic therapeutics are lacking. Several monoclonal antibodies (mAbs) targeting non-T2 cytokines were previously reported to be ineffective...
9.
Fricker M, Qin L, Sanchez-Ovando S, Simpson J, Baines K, Riveros C, et al.
Allergy
. 2021 Sep;
77(4):1204-1215.
PMID: 34510493
Background: Neutrophilic asthma (NA) is a clinically important asthma phenotype, the cellular and molecular basis of which is not completely understood. Airway macrophages are long-lived immune cells that exert important...
10.
Winter N, Gibson P, McDonald V, Fricker M
Int J Chron Obstruct Pulmon Dis
. 2021 Jul;
16:2165-2179.
PMID: 34321876
Purpose: The clinical and inflammatory associations of mast cells (MCs) and basophils in chronic obstructive pulmonary disease (COPD) are poorly understood. We previously developed and validated a qPCR-based MC/basophil gene...